Clinical trials regulatory environment ‘hostile’ and ‘oppressive’ – cancer specialist

Ireland is falling short of the target of six percent cancer patient involvement in clinical trials due to a hostile and oppressive regulatory environment, according to leading oncologist Prof John Kennedy. Despite the National Cancer Strategy setting a goal of six percent patient participation, only around two percent have access to trials nearly eight years into the strategy. The regulatory environment is described as under-resourced and labyrinthine, causing delays in setting up trials and discouraging companies from returning to Ireland. Commitments in the strategy, such as protected time for clinicians and adequate resourcing, are not being met, hindering progress in personalized cancer treatments. Additional funding requested for the National Cancer Control Programme was not received, impacting the ability to expand programs like screening.

Source link

error: Content is protected !!